Karyopharm Therapeutics Inc. Stock
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Karyopharm Therapeutics Inc..
Based on the current price of 0.54 € the target price of 12 € shows a potential of 2117.29% for Karyopharm Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Karyopharm Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -0.880% | -7.848% | -16.214% | -35.039% | -8.220% | -44.729% | -46.787% |
| Heron Therapeutics Inc. | -1.530% | 6.405% | 19.806% | -69.444% | -60.036% | -70.121% | -95.572% |
| Rhythm Pharmaceuticals | -1.680% | -8.556% | -13.198% | 14.765% | -8.556% | 292.202% | 519.565% |
Comments
Karyopharm Therapeutics (KPTI) had its price target lowered by Piper Sandler from $16.00 to $7.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm highlighted upcoming milestones for selinexor, including an ASCO late-breaking
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm said it will present fuller Phase 3 SENTRY data for selinexor in newly diagnosed
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in